The Company is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs. The Company was established on September 15, 2009. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 17, 2019.
Headquarters
512, B-Dong, 187, Techno 2-Ro, Yuseong-Gu, Daejeon
Daejeon; Daejeon;
Contact Details: Purchase the Synteka Bio Inc. report to view the information.
Website: http://www.syntekabio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service